11 Best Cancer Stocks to Buy Right Now

3. AstraZeneca PLC (NASDAQ:AZN)

Number of Hedge Fund Holders: 48 

AstraZeneca PLC (NASDAQ:AZN), headquartered in Cambridge, England, is a leading global biopharmaceutical company with a major role in the oncology sector. Its cancer portfolio covers lung, breast, gastric, and gastroesophageal cancers, with key drugs including Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu.

In the first half of 2025, AstraZeneca PLC (NASDAQ:AZN)’s oncology sales reached nearly $12 billion, up 16% year-over-year, driven by strong demand across its core therapies. New launches such as Truqap for breast cancer and Datroway for EGFR-mutated non-small cell lung cancer have also expanded its market presence, solidifying its position among the best cancer stocks to watch.

Regulatory and clinical progress further reinforced momentum. The FDA granted Priority Review for Imfinzi in early-stage and locally advanced gastric and gastroesophageal cancers, with a decision expected in late 2025. Positive Phase III results were reported for Enhertu (DESTINY-Breast09), Imfinzi (MATTERHORN), and camizestrant (SERENA-6), strengthening the business’s late-stage pipeline. Enhertu also showed the ability to delay breast cancer progression by 14 months, signaling potential label expansion.

Strategically, AstraZeneca PLC (NASDAQ:AZN) streamlined its pipeline by discontinuing early CAR-T and TCR-T candidates for solid tumors, redirecting investment toward high-potential immuno-oncology and targeted therapies.